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Abstract
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in 
developed countries. CLL is diagnosed with absolute B lymphocyte count (B-ALC) 
>5000/micrL sustained for at least 3 months, morphologically mature-appearing 
small lymphocytes, and flow cytometry showing the typical immunophenotype of 
CLL cells. Different prognostic parameters are used to differentiate between low-and 
high-risk patients, which would affect treatment decisions. Rai and Binet staging 
systems are the two most commonly used in practice. There has been a significant 
change in how we manage patients in CLL over the last 5 years. We have shifted away 
from chemoimmunotherapy toward novel agents such as BTK, PIK3, and BCL-2 
inhibitors, which are not only more efficacious but are also safer and better tolerated. 
New prognostic models are being developed, and it appears that minima residual 
disease (MRD) directed therapy will become the norm in the future. Many clinical 
trials are looking at various combinations of novel therapies, with a defined period of 
treatment based on MRD analysis, to enable patients to have a period of treatment-
free remission instead of continuous therapy. In this chapter, we summarize the latest 
updates in CLL management.
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1. Introduction
With an age-adjusted incidence of 4–5 per 100,000 population, chronic 
lymphocytic leukemia (CLL) is the most common type of leukemia in developed 
countries. The median age at diagnosis is 72 years, and more men than women (2:1) 
are affected [1]. CLL is one of the B-cell chronic lymphoproliferative disorders. It is 
characterized by a progressive accumulation of functionally incompetent lympho-
cytes, which are usually monoclonal in origin.
2. Diagnosis
CLL diagnosis depends on the presentation. For patients presenting with 
absolute lymphocytosis; CBC, flow cytometry of the peripheral blood, and exami-
nation of the peripheral smear are adequate to diagnose CLL [2]. Diagnosis of CLL 
using these tests requires identification of absolute B lymphocyte count (B-ALC) 
>5000/micrL sustained for at least 3 months, morphologically mature-appearing 
Advances in Hematologic Malignancies
2
small lymphocytes, and flow cytometry showing the typical immunophenotype of 
CLL cells: extremely low levels of surface membrane immunoglobulin (SmIg) and 
either Kappa or Lambda (but not both), CD19, CD20, CD23 and CD5 positive cells. 
Evaluation of the bone marrow is not usually necessary, but is included in the evalu-
ation of patients with unexplained cytopenias. Patients presenting with lymphade-
nopathy without lymphocytosis will need ideally an excisional lymph node biopsy 
or alternatively a needle biopsy showing mature lymphocytes with the previously 
mentioned phenotype to diagnose small lymphocytic lymphoma (SLL) which is 
considered by WHO the same disease as CLL with different manifestations [3].
Monoclonal B cell lymphocytosis is diagnosed when B-ALC is <5000/micrL 
persistently with no other manifestations of disease activity such as lymphade-
nopathy, hepatosplenomegaly, disease related cytopenias, or disease related 
symptoms. Patients with disease related cytopenias are diagnosed with CLL 
regardless of B-ALC and patients with any of the other manifestations are con-
sidered to have SLL [2]. Before 2008, the diagnosis of CLL was based on ALC 
equal or more than 5000/microL in the setting of appropriate immunophenotype. 
Patients with an absolute B lymphocyte count (B-ALC) less than 5000/microL 
and an ALC more than 5000/microL represented an overlap between CLL and 
monoclonal B cell lymphocytosis. The switch to using B-ALC for the diagnosis of 
CLL in 2008 eliminated this overlap [4, 5].
3. Prognostication
CLL is commonly thought of as an indolent disease associated with a prolonged 
clinical course and that patients with CLL will die from unrelated cause rather than 
the disease itself. It is important to know that this only happens in one third of the 
patients. More commonly, patients will have two phases of the disease: an initial 
asymptomatic phase (5–10 years) where the course will be benign, followed by the 
terminal phase (1–2 years) where performance status will decline due to recurring 
need for hospitalization. Some patients die quickly within 1–2 years of the diagno-
sis. Because of this variable natural clinical course of CLL, there have been always 
efforts to come up with reliable and clinically applicable criteria that would allow 
recognizing those patients with poor prognosis to start treatment as soon as possible 
and improve their survival and differentiate them from the other group where the 
prognosis is good and treatment can be delayed to avoid treatment toxicity [6–8].
3.1 Rai and Binet staging systems
Rai and Binet staging systems are the most commonly used systems in practice 
and the international workshop Group on CLL (iwCLL) recommends using an 
integrated system using both methods [9]. Both systems depend on findings of CBC 
and physical exam findings only, addition of CT scan of the chest, abdomen, and 
pelvis is not routinely recommended to stratify patients.
Rai staging system divides patients into 5 groups (Table 1). It was published 
initially in 1975, with initial reports showing one quarter of patients fall in stage 0 
on presentation, half of patients fall in stages 1 and 2, and a quarter of them fall in 
stages 3 and 4. Later reports showed that more patients fall in earlier stages because 
of earlier diagnosis due to the more routine testing being done in recent years 
including CBC [10]. Median survival decreases from almost 12 years in stage 0 to 
a year and a half in stages 3 and 4 [11]. In 1980s, this staging system was modified 
to include three stages based on actuarial survival pattern: Low risk (Rai stage 0), 
intermediate risk (Rai stages 1 and 2), and high risk (Rai stage 3 and 4). Of note, 
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if complete or partial remission is achieved with successful therapy, and a patient’s 
stage shifts from a higher risk to a lower risk category, the outlook for survival 
improves accordingly [12].
Binet staging system takes into consideration five potential sites of involvement: 
cervical, axillary, and inguinal lymphadenopathy (each area counts as one either 
unilateral or bilateral), spleen, and liver, in addition to the presence of anemia and/
or thrombocytopenia. Based on these factors, Binet staging system divide patients 
into three groups (Table 2) [13].
One important practical concept is to reliably differentiate between autoim-
mune cytopenias and cytopenias related to CLL because patients with autoimmune 
cytopenias have better outcome than Binet stage C patients although still worse 
than stage A and they can normalize their counts with treatments directed at the 
autoimmune cytopenia thus delay CLL treatment [14, 15].
Both systems are not very effective for predicting early disease progression. 
Although routine imaging is not recommended for staging of patients with CLL, 
visceral adenopathy may occur in early-stage disease and might predict an early 
disease progression. It is not known if the presence of visceral adenopathy warrants 
any specific change in therapy [16].
3.2 Other prognostic factors
Historically, the presence of CD38 by flow cytometry appeared to be indepen-
dently associated with an adverse prognosis as well as Increased levels of ZAP-70 
detected by flow cytometry [17]. It is a tyrosine kinase normally expressed by NK 
and T cells, and required for normal T cell receptor signaling. ZAP-70 is not nor-
mally expressed in B lymphocytes, but has been found in a subset of patients with 
CLL. The clinical significance of CD38 and ZAP-70 have declined overtime with 
better understanding of CLL cytogenetics.
Currently, we use cytogenetics, molecular studies, lymphocyte doubling time, 
and beta-2 microglobulin [18]. Patients with del(13q) have favorable outcome, 
patients with trisomy 12 have intermediate outcome while patients with del(11q) 
and del(17p)/P53 have poor outcome. The prognosis of patients with del(11q) has 
Stage Clinical features Median survival (in years)
0 (low risk) Lymphocytosis only >10
I and II (intermediate risk) Lymphadenopathy (I) and 
hepatosplenomegaly (II)
5–8
III and IV (high risk) Anemia (III), thrombocytopenia (IV) 1.5
Table 1. 
Rai staging system.
Stage Clinical features Median survival (in years)
A <3 areas of lymphadenopathy; no anemia or thrombocytopenia Comparable to age-matched 
controls
B Three or more areas of lymphadenopathy; no anemia or 
thrombocytopenia
7
C Hemoglobin <100 g/L or platelets <100 x 109 g/L 2
Table 2. 
Binet staging system.
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improved with the use of certain treatment regimens (e.g., fludarabine, cyclo-
phosphamide, rituximab) while that of del(17p) or TP53 mutations remains poor 
despite such treatments. Analysis of CLL8 trial showed worse outcome in patients 
with SF3B1 and RPS15 gene mutations. Also, patients with complex karyotype and 
NOTCH1 mutations have more aggressive course.
The lymphocyte doubling time is the number of months it takes the absolute 
lymphocyte count to double. Doubling time <12 months is associated with a progres-
sive course and a longer doubling time is associated with an indolent course. This 
factor is somewhat limited in usefulness because it takes time to measure. In patients 
with early stage disease, the presence of a short doubling time may favor more aggres-
sive therapy. Higher levels of Beta-2 microglobulin (B2M) are associated with poorer 
outcome. B2M should be interpreted with caution in the context of renal disease, or 
alternatively GFR-adjusted B2M can be used although lacks validation in prospective 
studies [19]. Moreover, approximately half of CLL clones will demonstrate unmu-
tated immunoglobulin heavy chain variable regions (IGHV), a finding associated 
with shorter survival overall and a higher risk of relapse following conventional treat-
ment, including chemoimmunotherapy and hematopoietic cell transplantation [20].
3.3 International prognostic index for chronic lymphocytic leukemia (CLL-IPI)
An international group of investigators did a comprehensive analysis [21] to 
develop a prognostic index for CLL. Using data from 3472 treatment naive patients 
participating in prospective, randomized clinical trials, five independent prognostic 
factors were identified: TP53 deletion or mutation, or both, IGHV mutational 
status, serum B2M concentration, clinical stage, and age. Using weighted grading of 
the independent factors, a prognostic index was derived that separated patients into 
four risk groups with significantly different overall survival at 5 years: low (93%), 
intermediate (79%), high (63%), and very high risk (23%). This chronic lympho-
cytic leukemia international prognostic index (CLL-IPI) has now been validated by 
several other groups and is expected to improve patient counseling and the plan-
ning of clinical trials. Other risk scores have been proposed, but none of them has 
been generally accepted. Of note, none of the scores (including the CLL-IPI) affects 
the decision of when to initiate therapy.
4. CLL therapy
4.1 Early evolution
In the 1940’s, steroids were the first systemic therapy for CLL. The risk of infec-
tion, other adverse effects from long term steroid use as well as transient nature of 
responses, steroids do not have a central role in the treatment of CLL. They can be 
used along with anti-CD 20 Ab to achieve remission in some patients.
Steroids were followed by the use of alkylating agent chlorambucil in the treat-
ment of CLL, either in combination or as a single agent. These treatments produced 
objective response rates but mostly resulted on partial responses [22, 23]. This was 
followed by a long time period before newer drugs were introduced in the treatment 
of CLL. Fludarabine has been used in various combinations to improve outcomes in 
CLL. When compared to CAP (cyclophosphamide, doxorubicin and prednisone), 
fludarabine showed favorable results [24]. Even when it was compared to chlo-
rambucil, fludarabine induced higher response rates but did not offer any survival 
advantage at the expense of higher toxicities especially from infection and neu-
tropenia [25]. Cladribine in combination with prednisone achieved response rates 
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similar to fludarabine when compared to chlorambucil but failed to demonstrate any 
survival benefit [26, 27]. Cyclophosphamide combined with fludarabine in previ-
ously untreated patients showed lower prevalence of residual disease and increased 
progression free survival (PFS) but again no benefit in overall survival (OS) [28]. 
When rituximab was combined with fludarabine and cyclophosphamide there was 
an improvement in PFS as well as OS [29]. This was observed across multiple phase 
3 randomized trials [30, 31]. Subset analysis of these trials led to the discovery that 
patients with mutated IGHV status, FCR led to long term remissions [30, 32].
4.2 Upfront treatment
Indication for treatment of CLL include severe fatigue, weight loss, night 
sweats, fever without infection, threatened organ function, progressive lymphade-
nopathy, anemia or thrombocytopenia that is progressive in nature, autoimmune 
anemia or thrombocytopenia not responsive to steroids [2]. In addition to these 
factors, patient age, performance status, presence or absence of del(17p) or TP53 
mutation, IGHV mutation status should be assessed prior to initiating treatment in 
patients with indications to treat. Imaging should be considered as well to evaluate 
disease burden.
4.2.1 CLL without del(17p) or TP53 mutation
The CLL 8 trial was a pivotal one that established chemoimmunotherapy as 
the standard of care for patients that can tolerate it. The FCR regimen (fludara-
bine, cyclophosphamide and rituxan) was compared against FC (fludarabine, 
cyclophosphamide). Previously untreated CLL patients were randomized to 
either receive 6 cycles of FCR or FC. The FCR regimen resulted in higher ORR 
(90% v/s 80%) and CR rates 94% v/s 22%). The median OS was not reached for 
FCR and was about 86 months for the FC regimen. Subset analysis showed that 
the maximal benefit was derived by fit patients with CLL, especially those with 
mutated IGHV [32]. The FCR regimen however has its share of side effects and 
cannot be given to older patients.
The CCL2M trial looked at the feasibility of Bendamustine-Rituxan (BR) in 
untreated CLL patients and the results were found to be encouraging [33]. This 
prompted its comparison to other treatment regimens. The MABLE study looked 
at BR versus Chlorambucil-Rituxan in patients ineligible to receive fludarabine. 
Complete response rates were higher in the BR arm (24%) as compared to the 
chlorambucil-rituxan arm. Overall response rate and overall survival were not 
different among the two arms. However the PFS (40 months v/s 30 months) and 
Minimal Residual Disease (MRD) negativity (66% v/s 36%) were higher in the BR 
arm as compared to the Chlorambucil- rituxan arm [34].
CLL10 trial compared BR with FCR. The primary end point was PFS with the 
objective to assess non inferiority of BR as compared to FCR. The trial confirmed 
the superiority of FCR therapy (Median PFS 55 vs. 42 months) in fit patients and 
in patients with IGHV mutated status. However, in patients over 65 years of age the 
toxicity profile was better with BR.
The CLL11 trial found that chlorambucil-obinutuzumab had better PFS 
(26.7 months) as compared to rituximab-chlorambucil (16.3 months). The PFS for 
chlorambucil monotherapy was the shortest (11.1 months). The obinutuzumab-
chlorambucil arm also had trend towards OS benefit as compared to the other 2 
arms. The study population included CLL patients with comorbidities [35]. Based 
on these 2 trials both BR and chlorambucil- rituxan or obinutuzumab-chlorambucil 
are acceptable alternatives in elderly patients or those with comorbidities.
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On a similar note, the COMPLEMENT 1 trial showed the combining ofatu-
mumab to chlorambucil in fludarabine ineligible patients showed better PFS 
(22.4 months) as compared to the monotherapy arm (13.1 months) [36].
However, with the advent of novel agents the landscape of treatment in 
CLL has significantly changed. The RESONATE-2 study compared single agent 
chlorambucil to ibrutinib which is a Bruton’s Tyrosine Kinase inhibitor. The 
ORR (92% v/s 36%) as well as PFS at 2 years (89% v/s 34%) in favor of ibrutinib 
(Figure 1). Based on the results of this study ibrutinib was approved for use in 
the first line setting of CLL. Results from the ECOG ACRIN Cancer research 
group trial E1912 were recently published. The study compared FCR versus 
Ibrutinib + Rituxan (IR) in treatment naive patients without deletion 17p. IR was 
found to be superior to FCR in all subgroups except for the IGHV mutated group. 
IR group saw significant less neutropenia and infectious complications as well as 
compared to FCR [38].
The alliance intergroup study showed that in older patients above 65, ibru-
tinib should be the standard of care as PFS was better in the ibrutinib arms 
then the BR arms [39]. However this study did not suggest a benefit of adding 
anti-CD 20 MAB therapy to ibrutinib monotherapy. In the older patient group, 
where chlorambucil is a treatment option, the iLLUMINATE trial showed that 
ibrutinib plus obinutuzumab combination resulted in better PFS as compared 
to chlorambucil plus obinutuzumab, albeit with greater serious adverse events 
[40]. Between the RESONATE-2 study and ECOG ACRIN study, ibrutinib has 
been established a first line recommendation in both younger as well as older 
patients with CLL.
Recently, CLL14 trial studied the combination of fixed-duration venetoclax 
and obinutuzumab versus obinutuzumab and chlorambucil in 432 treatment-naïve 
patients with CLL and coexisting medical conditions. Patients were evenly ran-
domized to receive 12 months of venetoclax alongside 6 months of obinutuzumab 
or 6 months of obinutuzumab followed by 6 months of chlorambucil. Results 
from the trial showed the venetoclax combination reduced the risk of disease 
progression or death by 67% versus obinutuzumab plus chlorambucil in patients 
with treatment-naïve CLL and co-existing medical conditions (HR, 0.33; 95% CI, 
0.22-0.51; P < .0001). The overall response rate (ORR) was 85% with venetoclax/
obinutuzumab versus 71% in the control arm (P = .0007). The complete response 
(CR) or CR with incomplete hematologic recovery (CRi) rates were 50% versus 
23%, respectively. The rate of minimal residual disease (MRD)-negativity in the 
bone marrow was 57% in the venetoclax arm compared with 17% in the obinutu-
zumab/chlorambucil arm. The MRD-negativity rates in the peripheral blood were 
Figure 1. 
Progression-free survival of Ibrutinib vs. Chlorambucil [37].
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76% versus 35%, respectively. Venetoclax and obinutuzumab combination is the 
only chemotherapy-free option with fixed duration that proven to provide such a 
durable response.
4.2.2 CLL with del(17p) or TP53 mutation
Ibrutinib provides durable responses and is well tolerated in patients with 
del(17p). Historically this group of patients generally have poorer outcomes as 
compared to patients with CLL but without del(17p) [41]. Other treatments in the 
front-line setting are listed in NCCN for these patients however none of them are 
very effective. The CAPTIVATE trial is currently on going looking at venetoclax 
along with ibrutinib in the upfront setting.
Is summary, as far as front line therapy is concerned, for fit patients with IGVH 
mutated status it is reasonable to use chemo-immunotherapy such as FCR or BR. All 
other patients including young or older patients with high risk disease such as those 
with unmutated IGHD, 17p del or p53 mutation or 11q deletion it’s recommended to 
treat with a novel agent such as ibrutinib as there has been accumulating evidence 
of better efficacy when compared to chemoimmunotherapy alone.
4.3 Relapsed or refractory chronic lymphocytic leukemia
4.3.1 Definitions
The International Workshop on CLL (iwCLL) defines relapsed disease when it occurs 
in patients who have previously achieved either a complete or partial remission but 
then develop progressive disease after a period of 6 months or more. Patients who fail to 
achieve either a partial or complete remission with therapy or those who develop disease 
progression within 6 months of last therapy are defined to have refractory disease. This 
distinction is principally made because many patients with progressive disease occurring 
later after the discontinuation of treatment can be successfully retreated using the same 
medication, or by switching to other available treatments. In contrast, patients who have 
refractory disease are unlikely to respond to a trial of the previously used therapy and 
have a much poorer prognosis [2]. Of note, The iwCLL response criteria were originally 
developed using data from patients treated with single agents (i.e., fludarabine, chloram-
bucil). As first-line therapy has evolved, the overall response rate and median progres-
sion-free survival have increased. The definitions of relapsed and refractory disease will 
likely change as therapy improves especially that we depend on expected progression 
free survival (PFS) in practice more than the 6 months rule to choose the next regimen as 
illustrated below.
The choice of treatment at relapse should consider how soon the relapse happens 
after initial treatment. If it happens sooner than the expected median PFS for the 
specific regimen is considered “Early relapse”, while it is considered “Late relapse” 
when it happens after the expected median PFS [42]. Prospective trials have 
reported median PFS for different regimens, as a rule of thumb, progression within 
2–3 years of initial treatment with fludarabine, cyclophosphamide, and rituximab 
(FCR) or within 1 year of other chemoimmunotherapy regimens may be considered 
to have early relapse.
4.3.2 Targeted therapies of relapsing or refractory CLL
For early relapsing CLL, it’s recommended to start a targeted therapy with either 
ibrutinib, idelalisib plus rituximab, or venetoclax with or without rituximab rather 
than retreatment with the prior therapy or a trial of another chemoimmunotherapy 
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regimen. One series reported the median survival of 42 patients unresponsive to 
fludarabine as 48 weeks and only 11% responded to other chemoimmunotherapies 
[43]. The optimal length of treatment has not been defined but common practice to 
continue until disease progression or unacceptable toxicity.
Ibrutinib: it is a common treatment of choice for patients with refractory or 
early relapsing disease. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor 
[44]. The RESONATE trial which is a multicenter open label phase III trial showed 
better overall response rate (ORR), PFS, and overall survival (OS) compared to 
ofatumumab (an anti-CD20 monoclonal antibody) in patients with refractory/
relapsed CLL, these benefits were found across all subgroups of patients, includ-
ing those with high-risk features such as del(17p). This late observation was 
confirmed in the RENONATE-17 trial in 2016 where ORR was 83% at a median 
follow up of 28 months in 144 patients with relapsed/refractory CLL/SLL with 
del(17p) [45, 46]. Expected side effects from ibrutinib include diarrhea, fever, 
and nausea. Higher rates of atrial fibrillation (6–16%) and pneumonitis were 
noted in the clinical trials [47], atrial fibrillation is usually manageable without 
discontinuation of the drug. Another important side effect is increased risk of 
bleeding, ibrutinib should be used with caution if patient is on one anti-platelet 
medicine and should be avoided if on two anti-platelets or anticoagulants as 
fatal cases of bleeding happened in those scenarios. Also, Ibrutinib should be 
discontinued 3–7 days before and after surgery to decrease risk of perioperative 
bleeding. Patients should be also reminded to avoid NSAIDs [48]. Ibrutinib is 
associated with a usually “transient” lymphocytosis that peaks after approxi-
mately 4–8 weeks and resolves in the majority despite continued drug exposure 
with a median duration of 14 weeks. The starting dose of ibrutinib is 420 mg 
orally once daily, except for patients with mild liver impairment (child-pugh class 
A), the starting dose is reduced to 140 mg daily since it’s metabolized in the liver 
and is contraindicated in moderate to severe liver impairment.
Idelalisib: It is an oral inhibitor of phosphoinositide 3′-kinase (PI3K) delta. It 
is given in combination with Rituximab. A phase 3 multicenter trial compared 
Idelalisib and rituximab vs. placebo and rituximab in 220 patients with relapsed 
CLL showed superior ORR, PFS, and OS (81%, 93%, and 92%, respectively), these 
benefits were seen in all prespecified subgroups, including those with 17p deletion, 
TP53 mutation, and IGHV mutations [49]. Possible side effects include: pneumonia 
and febrile neutropenia most commonly, but also fatigue, nausea, and diarrhea have 
been reported. Idelalisib can cause severe elevations in AST and ALT, it is reversible 
on holding the drug and never led to permanent discontinuation in clinical trials. 
The starting dose is 150 mg twice daily. Other possible combinations are Idelalisib 
plus Bendamustine plus Rituxan or idelalisib plus ofatumumab, those combinations 
led to more grade 3 toxicities and treatment related deaths, respectively, so extreme 
caution should be paid while choosing patients for these combinations [50, 51]. As 
with ibrutinib, idelalisib can cause transient lymphocytosis that peaks in the second 
week of treatment and resolves spontaneously by week 12, adding Rituximab 
decrease its severity and shortens its duration. CMV monitoring and prophylaxis 
against Pneumocystis pneumonia (PCP) are important with idelalisib use. It carries 
a boxed warning regarding hepatotoxicity, colitis, and pneumonitis.
Duvelisib: it is an oral inhibitor of PI3K delta and gamma isoforms. The phase 
3 DUO trial was the largest trial to study the efficacy of duvelisib, it included 319 
patients assigned to duvelisib vs. ofatumumab. Duvelisib had higher ORR and 
median PFS (74% and 13.3 months, respectively) [52]. Duvelisib is usually reserved 
for patients with multiply relapsed disease, usually after treatment with ibrutinib 
and venetoclax, with or without prior chemoimmunotherapy. The starting dose 
is 25 mg administered orally twice a day over a 28-day treatment cycle. Toxicities 
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include opportunistic infections, diarrhea or colitis, cutaneous reactions, and 
pneumonitis. Hepatic function and blood counts must be monitored for hepato-
toxicity and neutropenia. Like idelalisib, it is recommended to use PCP and CMV 
prophylaxis.
Venetoclax: it is an oral inhibitor of BCL2, an antiapoptotic protein that is patho-
logically overexpressed and that is central to the survival of CLL cells. Initial phase 
2 trials showed ORR more than 65% for venetoclax [53, 54]. The MURANO trial, an 
international phase 3 trial, compared Venetoclax plus rituximab vs. bendamustine 
plus rituximab in 389 patients with relapsed/refractory CLL showed higher PFS of 
85% and OS of 92% at 2 years for the venetoclax arm, this effect was maintained in 
high risk patients and older adults. Patients assigned to venetoclax arm were also 
more likely to achieve undetectable minimal residual disease (uMRD) which is a 
status predictive of superior PFS [55]. The most common toxicities are pancytope-
nia, diarrhea, and upper respiratory tract infection. Because venetoclax increases 
risk of TLS, high risk patients (i.e. any lymph node >10 cm or lymph node >5 cm 
and ALC >25 x 109/L) should receive the first few doses in the inpatient setting with 
IV hydration, use of allopurinol or rasburicase, and frequent monitoring of TLS 
labs. Venetoclax is started at 20 mg daily and increased gradually over 5 weeks to a 
final daily dose of 400 mg. Rituximab is started after the patient has completed the 
escalation schedule and received the 400 mg dose for 7 days. It is common practice 
to use venetoclax after ibrutinib failure.
4.3.3 Late relapse: Retreatment versus targeted therapy
Although both options are valid in late relapsed CLL patients, each option has its 
advantages and disadvantages. Targeted therapy is generally the preferred option 
because they have better PFS and may improve OS, the best example on that is the 
MURANO trial mentioned above, patients who relapsed after 24 months of initial 
treatment with bendamustine and rituximab were included in the study, and still 
they had better PFS and OS [55]. Targeted therapy also offers the convenience of an 
oral regimen. On the other hand, retreatment with initial chemoimmunotherapy 
regimen may be considered for patients who experienced minimal toxicity with 
the initial treatment, targeted therapy is associated with unique toxicities and is 
often administered without breaks until the time of progression. In a phase 2 study, 
patients who were initially treated with FCR and relapsed after 3 years showed 
median survival of 5 years and estimated five-year survival rate of 70% when they 
were retreated with FCR, although the toxicities, especially myelosuppression, were 
more frequent [56].
Fludarabine-based therapy: Fludarabine, cyclophosphamide, plus rituximab 
(FCR) is a preferred treatment option for younger patients (<70 years) with 
standard-risk CLL. Patients with del(17p) or TP53 mutations have particularly 
poor outcomes following fludarabine-based therapy and should be considered for 
targeted therapy.
Bendamustine-based therapy: Bendamustine plus rituximab (BR) is an accept-
able alternative to fludarabine-based regimens among patients with decreased renal 
function or other comorbidities. BR is well tolerated, but appears to be slightly less 
effective than fludarabine-based regimens [57]. The most common toxicities are 
neutropenia, thrombocytopenia, and anemia [58]. Infusion is associated with a 
hypersensitivity reaction in approximately 5% of patients.
Ofatumumab-based therapy: Single agent ofatumumab has demonstrated 
partial response rates of approximately 50% in patients with relapsed or refractory 
CLL, although response duration is usually short [59]. The combination of ofatu-
mumab plus chlorambucil is expected to result in higher response rates.
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Figure 2. 
Hematopoietic SCT for CLL by year [64, 65].
Patients with CLL experience serial relapses and many will be treated with each 
of these agents at some point during their disease course. A preferred order for their 
use has not been established. A choice is primarily made based on the patient’s prior 
treatment and the regimens’ expected toxicities.
5. Role of transplant in CLL
In the setting of approval of novel agents in the treatment of CLL the number of 
transplants that are being performed in Europe and the United States are decreas-
ing. In the chemoimmunotherapy era, patients with TP53 deletion/mutation, 
fludarabine refractoriness, early relapse (<24 months) after FCR treatment were 
in the highest risk group. Allogeneic Stem Cell Transplant (SCT) would be con-
sidered in these patients as the only viable treatment option. Today however, these 
patients have ibrutinib, idelalisib and venetoclax and various combination of novel 
agents with immunotherapy as possible treatment options. There are no random-
ized clinical trials that compare the outcomes of allogeneic SCT with conventional 
chemotherapy, chemoimmunotherapy or novel therapy regimens. Most transplants 
offered for CLL use reduced intensity conditioning (RIC), however no trials have 
been conducted to compare it to myeloablative conditioning. RIC resulted in 
reduced toxicity without compromising engraftment and anti-tumor activity [60]. 
Follow up results for studies with RIC indicate that about 40% of patients achieve 
long term disease control and RIC also overcomes the negative prognostic effect of 
TP53, fludarabine refractoriness as well as that of SF3B1 and NOTCH gene muta-
tions [61–63]. Generally, allogeneic transplants are no longer offered to patients 
with del(17p) in first remission. In the relapsed setting the role of SCT must be 
weighed against the comorbidities, prior therapies, and duration of response to 
prior therapies as well as current mutation status including TP53, NOTCH1 and 
SF3B1. Patient must be informed about the side effect profile and non-relapse 
mortality associated with allogeneic transplant compared to the toxicity and side 
effect profile of novel agents. (Figure 2).
6. Role of minimal residual disease (MRD) testing in CLL
MRD in CLL is assessed most commonly using multiparametric flow cytometry 
with a sensitivity to detect <1 CLL cell in 10,000 leukocytes. MRD – undetectable 
(MRD-U) has been defined detection of <1 CLL cell per 10,000 leukocytes [2]. 
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MRD-U in the blood or bone marrow strongly correlates with longer PFS in the 
patients treated with chemoimmunotherapy has been noted in numerous studies 
[30, 57, 64]. However, MRD- U is rarely achieved in patients who are on ibrutinib, 
a drug that offers significant clinical benefit in PFS and survival in CLL patients 
[66]. So, there is consensus that while MRD- U is generally a favorable outcome for 
patients but its exact use case scenario in clinical practice is yet to be determined. As 
of now the potential use of MRD status in CLL patients is in the context of clinical 
trials, as a surrogate for PFS depending on the type of treatment used and possibly 
as a replacement for clinical and radiographic response assessments in the future.
7. Richter’s transformation
Maurice Richter initially described the transformation of CLL into an more 
aggressive form of lymphoma and since then this has been recognized as Richter’s 
Transformation (RT) [67]. In most cases RT consists of transformation of CLL into 
Diffuse Large B Cell Lymphoma (DLBCL), however other aggressive lymphomas 
have been reported. As of now the reported incidence of RT in the era of novel 
agents is not very different from the incidence of RT in the chemoimmunotherapy 
era [68, 69] with incidence rates varying from 3–20% among various studies. RT is 
suspected when there is rapid clinical deterioration, worsening discordant lymph-
adenopathy to new onset cytopenia. However, its presentation can be varied. When 
RT is suspected a comprehensive evaluation with a PET/CT, image guided biopsy as 
well as a bone marrow biopsy is required. SUV of greater than 10 can distinguish RT 
form CLL with high sensitivity (91%) and specificity (95%) [70]. However, this has 
been disputed in the setting of novel agents and thus a concern for RT necessitates 
a biopsy of the index lesion preferably. RT primarily arises in the background of 
TP53 disruption and complex karyotype. MYC activation and CDKN2A/B likely 
play an important role in RT. Clonally related RT patients (>80% of RT DLBCL) 
respond very poorly to traditional chemotherapy for DLBCL, whereas clonally 
unrelated DLBCL RT patients respond to traditional chemotherapy just as de novo 
DLBCL. Thus, determination of clonal evolution is important but difficult to deter-
mine [71].Trials performed prior to the use of novel agents used R-CHOP or similar 
Figure 3. 
Richter transformation. Adapted by ASH education handbook [73].
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regimens as the standard therapy to treat RT. Fit patients who achieve a complete 
response or good partial response achieve benefit from a post induction strategy 
involving stem cell transplant [72]. Novel combinations, PDL-1 blockade and 
CAR-T or bispecific antibodies are being currently investigated as potential treat-
ment options [72]. Figure 3 below shows a suggested treatment approach algorithm 
for suspected patients with RT.
8.  Hypogammaglobulinemia and autoimmune hemolytic anemia 
(AIHA)
8.1 CLL and hypogammaglobulinemia
Hypogammaglobulinemia is the most predominant inherent immune 
defect in CLL patients, with subtypes IgG3 and IgG4 particularly affected. 
Hypogammaglobulinemia becomes more pronounced with longer disease duration 
and advanced-stage disease. There is generally no reversal in this defect, even with 
response to therapy. However, in one report, ibrutinib therapy resulted in partial 
reconstitution of humoral immunity, with an increase in IgA levels [73]. The most 
common site of infection in CLL patients is the respiratory tract, which may be 
related to serum IgA and IgG4 deficiencies and possibly to mucosal immune defects. 
The majority of patients with CLL will develop hypogammaglobulinemia at some 
point in the course of their disease. The use of prophylactic intravenous immuno-
globulin (IVIG) to restore IgG levels is controversial. For most patients with CLL, 
prophylactic IVIG is not recommended. For patients with CLL who have had recur-
rent infections requiring intravenous (IV) antibiotics or hospitalization and who also 
have a serum IgG <500 mg/dL, it is reasonable to administer IVIG. The usual dose is 
200–400 mg/kg by IV infusion, given at three- to four-week intervals. The goal is to 
maintain the trough serum IgG in treated patients above 500–700 mg/dL as a general 
guideline. If there is a substantial decrease in the incidence of infections, treatment 
at gradually extended intervals may be considered. There is no good endpoint for 
when such therapy can be discontinued. The randomized trials of prophylactic 
IVIG found that patients who receive IVIG have a decreased incidence of minor and 
moderate, but not major, bacterial infections. However, IVIG does not appear to 
increase quality of life or survival [74]. Potential toxicities related to IVIG include 
anaphylaxis, fever, chills, “flu-like” symptoms, and headache. Another important 
aspect of IVIG therapy is that it replaces neither IgM nor IgA.
8.2 CLL and AIHA
CLL is frequently associated with autoimmune phenomena, the most common 
being autoimmune hemolytic anemia (AIHA) [75]. Up to 33% of CLL cases have a 
positive direct antiglobulin test (DAT) during the course of disease, but overt AIHA 
occurs much less frequently. In a report of 1203 patients with CLL consecutive cases 
reported from a single institution, 52 (4.3%) cases of AIHA were observed, 19 at 
the time of diagnosis [76]. The prevalence of AIHA in patients with CLL have been 
reported in the range of 4–10%. It increases with disease stage. The autoantibodies 
that cause AIHA can be produced by nonmalignant B cells or, less commonly, by the 
malignant CLL clone itself [77, 78]. In practice, AIHA may occur in patients with no 
other requirement for treatment, or in patients in whom chemotherapy treatment is 
imminent or already started. Factors associated with an increased risk of develop-
ment of AIHA at diagnosis included a high white blood count, older age, and male 
sex. AIHA alone was not itself associated with poor prognosis. The diagnosis of 
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AIHA is usually based on the presence of an isolated fall in hemoglobin associated 
with a positive DAT, increased reticulocytes, and serum bilirubin. There have been 
no controlled trials of treatment for AIHA in CLL and the treatment approach is 
based on personal and institutional experience. In general, AIHA is responsive to 
CLL treatment, but if there is no indication to treat CLL, AIHA should be treated 
as a separate entity with steroids and other immune suppressants, the details of 
which is beyond the scope of this chapter. There has been controversy whether 
some chemotherapy agents, particularly purine analogs, induce or worsen AIHA. In 
a trial comparing outcomes of treatments using chlorambucil, fludarabine, or 
fludarabine in combination with cyclophosphamide, a positive DAT was found in 
14%, and AIHA occurred in 10% of patients [75]. AIHA occurred more often in 
patients treated with chlorambucil than fludarabine, and occurred least frequently 
in patients receiving the combination of fludarabine and cyclophosphamide. For 
patients requiring therapy, a positive DAT test had poor prognostic significance, 
even in the absence of AIHA. The results suggest that the most successful treatment 
of AIHA in patients requiring chemotherapy treatment is the treatment associated 
with the best response rate.
9. Future directions
In summary, there has been a significant change in how we manage patients 
in CLL over the last 5 years. We have shifted away from chemoimmunotherapy 
towards novel agents such as BTK, PIK3, and BCL-2 inhibitors, which are not only 
more efficacious but are also safer and better tolerated. New prognostic models are 
being developed, and it appears that MRD directed therapy will become the norm 
in the future. Many clinical trials are looking at various combinations of novel 
therapies, with a defined period of treatment based on MRD analysis, to enable 
patients to have a period of treatment-free remission instead of continuous therapy.
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